Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
株式のランク #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
株価
$0.378
最終同期: 2024-05-24
時価総額
$618.41K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 NeuBase Therapeutics, Inc. (NBSE)

カテゴリー

NeuBase Therapeutics, Inc.(NBSE)の株式分割履歴
NeuBase Therapeutics, Inc.株(シンボル:NBSE)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 14, 2026に行われました。
Aug 14, 2026より前に購入されたNBSE株は、現在0NBSE株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE